Program Overview
This CME/CNE program will provide learners with an update regarding treatment and management of patients with hepatocellular carcinoma (HCC) through an interactive panel format. The expert faculty will first set the stage for modern day HCC care, reviewing the science, prevalence and current treatment guidelines. Recent clinical trial data of first line, second line and combination therapies will be analyzed along with emerging therapeutics, with the clinical implications debated among the panel. Best practices for managing adverse events through an interprofessional approach will be relayed. At the conclusion of this CME/CNE activity, learner’s will be better equipped to implement optimal, team-based care in clinical practice.
Target Audience
Oncologists, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with HCC
Learning Objectives
- Analyze recent data of current and emerging therapeutic options for the treatment of HCC
- Apply effective treatment strategies to improve outcomes for patients with HCC
Faculty
Ghassan K. Abou-Alfa, MD (Course Chair)
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York
Alison Clemens, RN, OCN
Memorial Sloan Kettering Cancer Center
New York, New York
Amit Singal, MD
Medical Director, Liver Tumor Program
Clinical Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
| Faculty | Relationship Identified With: | |
| Ghassan K. Abou-Alfa, MD |
|
|
| Alison Clemens, RN, OCN | Nothing to disclose. | |
| Amit Singal, MD | Consultant/Advisor: AbbVie Inc; Bayer AG; Bristol-Myers Squibb Company; Eisai, Inc.; Exact Sciences Corporation; Exelixis, Inc.; Gilead Sciences, Inc.; Glycotest, Inc.; Roche; Wako Diagnostics U.S.A Corporation |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hours). Provider number P0491.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
Financial Support
This activity has been supported by independent educational grants from Bristol-Myers Squibb Company and Eisai Co., Ltd.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Bristol-Myers Squibb Company and Eisai Co., Ltd. do not recommend the use of any agent outside of the labeled indications
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
